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The human class II genes encode heterodimeric glycoproteins that belong to
at leastthree major HLA-class II families : the HLA-DR, -DQ,and -DP molecules .
They play a central role in antigen presentation and in the control of immune
responsiveness . Immune reactions are initiated after antigen presentation to the
TCR by accessory cells (APC) in the context of class II molecules (1, 2) .
Progress in the molecular genetics of HLA class II genes has clarified the
genetic organization of theHLA-D region (3) . The molecular basis for the allelic
polymorphism at the individual class II loci has now been analyzed directly at
the DNA sequence level and by oligonucleotide hybridization (4, 5) . Two
expressed DR ,B loci have been identified and linked in the HLA-DRw52
supertypic family (6) . LocusDR ,BI encodes the well-known DR specificities DR3,
w5, and w6, while locusDR #III encodes the supertypic specificity HLA-DRw52
(7) . The latter has recently been shown by DNA sequence analysis to include at
least three alleles, called 52a, 52b (4), and 52c (Gorski, J ., et al ., manuscript in
preparation), which can be identified by oligonucleotide typing (5, 8, 9). HLA-
DR protein heterogeneity has also been observed by two-dimensional (2-D)' gel
electrophoresis (10, 11).
The identification of this molecular and genetic HLA-DR 0 polymorphism in
DRw52 haplotypes has prompted us to investigate in detail its functional aspect.
To this end, T cell clones were isolated after in vitro tetanus toxoid (TT)
restimulation of PBMC from immune donors . This study focuses on the corre-
lation between the functional and the structural polymorphism within DRw52
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haplotypes, by comparing the pattern of reactivity of selected TT-specific, HLA-
DR3- and DRw52-restricted T cell clones with the pattern of allele-specific
hybridization with oligonucleotides in panel and family studies. The specificity
of the antigen specific clones was also compared with that of the LB-Q1-
alloreactive T cell line RT279 that was previously shown to recognize a subset
of cells within DRw52 (12). The data presented show that the majority of the T
cell clones isolated are restricted by epitope(s) of the DR ,d1 locus (DR3), but that
other clones are clearly restricted by DR ,8111 (DRw52) locus products. These
clones can distinguish between the allelic products of locus DR (3111. The
correlation between this functional polymorphism and the molecular basis for
allelic diversity of the two DR ,B chain gene products is discussed.
Materials and Methods
Generation of T Cell Clones.
￿
Cultures were carried out at 37 ° C in an H2O-saturated,
5% COQ atmosphere. RPMI 1640 (Gibco AG, Basel, Switzerland) supplemented with 15%
human AB' serum from male untransfused volunteer donors and antibiotics was used as
culture medium (CM). PBMC were obtained from volunteer donors by venipuncture
aspiration of blood on heparin (10 IU/ml Liquemin Roche, lot number B0155 S.A.; F.
Hoffmann-La Roche & Co AG, Basel, Switzerland) density centrifugation over Ficoll-
Hypaque (No. 26239; Pharmacia Fine Chemical AB, Uppsala, Sweden), two washes in
PBS, and suspension in CM . PBMC from selected donors were restimulated in 10 ml of
CM and placed in 30-ml culture flasks (Corning 25100; D. V. Kobrin SA, Chambesy,
Switzerland) as follows: 10' responders were cocultured with 10' autologous cells that
have been previously incubated during 4 h with TT (Number FV.2 ; Institut Merieux,
Lyon, France), at a dilution of 1 :2,500 (unless otherwise indicated), washed three times
in CM, followed by irradiation (35 cGy). After 4 d of culture, the cells were harvested
and T cell blasts were isolated by density gradient flotation using a Percoll gradient
(Number 26239; Pharmacia Fine Chemical AB). Cells layering at the interphase between
50 and 55% (consisting mostly in blasts) were harvested, washed three times in CM, and
used for cloning in limiting dilution culture. Autologous irradiated and TT-pulsed PBMC
(104/well) were dispensed together with 0.3 blasts/well into 72-well microtiter culture
grade Terasaki microculture trays (model F 3034 Microtest; Falcon Labware, Oxnard,
CA) in a total volume of 20 u1 of CM supplemented with 15% of an IL-2-containing
culture supernatant (Lymphocult T, number 115074 ; Biotest Serum Institut, Frankfurt,
Federal Republic of Germany). After 7 d the wells were inspected microscopically for
growth, and confluent cultures were transferred into flat-bottomed, 96-well, 200-WI
microculture trays (Falcon Labware 3070) containing Lymphocult-supplemented CM.
Growing cultures were then tested for TT specificity with the autologous APC, incubated
either with diphtheria toxoid, (1 :5,000 dilution), candida antigen, (1 :5,000 dilution),
Proteus antigen, (1 :100 dilution), trichophyton antigen, (1 :5,000 dilution) (Institut Mer-
ieux) tuberculin (40 U/ml; Statens Seruminstitute, Copenhagen, Denmark), or TT as
described above.
HLA Typing.
￿
PBMC from volunteer blood donors were HLA typed using the standard
National Institutes of Health (Bethesda, MD) complement-mediated microcytotoxicity
assay (13).
Cryopreservation.
￿
PBMC and T cell clones were stored in the vapor phase of liquid
nitrogen in 1-ml vials containing 5-10 x 106 cells suspended in CM supplemented with
10% DMSO (E. Merck, Darmstadt, Federal Republic of Germany).
Homozygous Typing Cells (HTC). PBMC from the HLA homozygous donors AVL,
QBL, CAA, HHK, HAR were kindly provided by J. J. van Rood, Department of
Immunohematology, University Medical Center, Leiden, The Netherlands, and by G. B.
Ferrara, Instituto Nazionale per la Ricerca sul Cancro, Genova, Italy).
Monoclonal Antibodies (mAb). We gratefully acknowledge the gift of the following
mAbs for these studies. Their specificity and origin is indicated in brackets: Tu 22 (DQ)IRLk ET AL. 855
and Tu 35 (DR; from A. Ziegler, reference 14), B7/21 (DP; from N. Reinsmoen, reference
15), D1/12 (DR; S. Carrel, 16), GSP4.1 (DR; Genetic Systems Corp., Seattle, WA, 17),
7 .3.19.1 (DRw52-like; H. Bruning, 18), 16.23 (DR3 and some DRw6 ; J. Johnson, 19),
NDS 10 (some DRw52 ; S. V. Fuggle, manuscript submitted for publication). These
antibodies were provided in form of ascites and tested after dialysis against PBS and
centrifugation. The dilutions ofascites that were tested are indicated in the figures of the
result section. mAb.OKT-2, 3, -4, and -8 were purchased from Ortho Diagnostics Systems
Inc., Westwood, MA.
Immunofluorescence. All manipulations were performed at 4 ° C. 105 cells were sus-
pended in PBS containing 5% BSA and stained in two steps for indirect immunofluores-
cence at 4°C according to standard procedures. Cells were stained first with 5% goat
serum-PBS and mAb, washed three times, then washed three times with goat anti-mouse
Ig (GAMIg) conjugated to FITC (Coulter Clone; Coulter Immunology, Instrumenten
Gesellschaft AG, Zurich, Switzerland) and suspended in 5 ml PBS for cytofluorometric
analysis (EPICS-V; Coulter Electronics, Hialeah, FL). Control samples stained only with
GAMIg-FITC were analyzed in parallel. At least 105 positive events were analyzed. The
analyses were kindly performed by Dr. D. Wohlwend, Centre de Cytofluorometrie, CMU,
Geneva, Switzerland.
TCell Proliferation Assay.
￿
Freshly thawed T cell clones (2 X 104) were mixed with TT-
preincubated washed and irradiated PBMC (5 X 1 )4) and dispensed in 200 A1 of CM into
triplicate wells of a 96-well, round-bottomed microculture plate (Linbro No. 76-018-04;
Flow Laboratories AG, Zug, Switzerland). After 48 h of coculture, 1 ACi of [8H]TdR (TR
120; Amersham International Ltd., Amersham, UK) was added into each well and cultures
were harvested on glass filters 8-12 h later. [8H]TdR incorporation was determined by
liquid scintillation spectroscopy. Results are expressed in counts per minute, unless
otherwise indicated.
TCell Functional Blocking Studies.
￿
Antigen-pulsed and irradiated stimulator cells were
incubated with mAbs or CM for 1 h and washed three times, unless indicated otherwise.
Responder clones (2 X 104) were added to 5 X 104 stimulators for a T cell proliferation
assay (see above). The percent relative response of the responder clones to TT-APC in
the presence of mAbs was calculated as follows: Percent relative response = 100 X [(cpm
test + mAb)/(cpm CM control)]. Where cpm test +mAB is [8H]TdR incorporation of mAb-
exposed cultures in the presence of antigen, less [8H]TdR incorporation of mAb-exposed
cultures without antigen, and where cpm CM control is [8H]TdR incorporation of CM-
treated cultures with antigen, less [8H]TdR incorporation of CM-treated cultures without
antigen.
Stimulation with INF-y.
￿
PBMC were cultured for 20 h before antigen exposure in the
presence of 250 U/ml of rINF-y (generous gift of Biogen SA, Geneva, Switzerland).
Oligonucleotide Typing.
￿
DNA was prepared as described previously by M. Gros-Bellard
et al. (20) from the B cell lines AVL and QBL and from granulocytes or PHA blasts or
LCL derived from volunteer blood donors who were HLA-typed in our laboratory. DNA
was digested with Eco RI (Boehringer AG, Mannheim, Federal Republic of Germany),
electrophoresed in 0.7% agarose gels in Tris-borate/EDTA buffer (pH 8.3) and trans-
ferred to Gene Screen Plus (New England Nuclear, Boston, MA) membranes in 0.4 M
NaOH, 0.6 M NaCl. Oligonucleotide 52a probe is complementary to the sequence
GGAGCTGCGTAAGTCTGAG of the HLA-DRw52a allele at positions 11-29 of the
HLA DR#III locus; oligonucleotide 52b is complementary to the sequence
GTTCCTGGAGAGACACTTCC of the DRw52b allele at positions 62-81 ; and oligo-
nucleotide 52c is complementary to the sequence GTTCCTGGAGAGATACTTCC of
the DRw52c allele at positions 62-81 of the HLA DRSIII locus (Gorski, J., et al.,
manuscript submitted for publication; 4, 21). Oligonucleotides were end labeled with y-
[82P]ATP (sp act = 5,000 Ci/mmol; Amersham International; 1Ci = 37 GBq) by T4
polynucleotide kinase (Pharmacia Fine Chemical AB) to a sp act of 5 X 108 cpm/Wg.
Prehybridization and hybridization with the labeled oligonucleotides (1 .5 X 108 cpm/ml)
were performed as described (5) except that dextran sulfate was omitted and only 5%
NaDodSo4 (wt/vol) was used in both prehybridization and hybridization solutions. The
membranes were washed for 1 h at 50 °C (oligonucleotide 52b: 53°C) in 3X NaCl/Cit856 FUNCTIONAL POLYMORPHISM OF THE TWO DR 0 GENE PRODUCTS
(1X NaCI/Cit = 150 mM NaCl, 15 mm trisodium citrate, pH 7.0), 10X Denhardt's
solution, 5% (wt/vol) NaDodSo4, 25 mM sodium phosphate (pH 7.0), and then for 1 h at
50°C (oligonucleotide 52b: 53°C) in Ix NaCI/Cit, 1% NaDodSo4 (9). Autoradiography
was done for 5-15 d on preflashed X-AR5 Kodak films, using CAWO SE4 intensifying
screens.
Results
Generation of T Cell Clones Specific for TT and Restricted by DR3-associated
Epitopes. PBMC from two donors immune to TT (d.1417 and d.2778) were
selected for these studies. These donors differed for the DR3-associated haplo-
types (d.1417: HLA-AI,-;B8,21 ;DR3,-;DQw2,-/d.2778: HLA-A2,3;B5,12;
DR3,6;DQw1,2). Their PBMC were restimulated in vitro with TT and cloned
exactly as described (Materials and Methods). After cloning of d.1417 PBMC,
44 TT-specific clones (50% cloning efficiency) were obtained, and 11 TT-specific
clones (cloning efficiency 19%) were derived from PBMC of d.2278 . Of these
55 clones, 17 from d.1417, and 7 from d.2278 could be expanded sufficiently
and screened for TT-specific proliferation against a panel of irradiated allogeneic
PBMC from unrelated donors. This panel of PBMC was designed to allow
selection of clones restricted by DR but not DQ determinants. We therefore
included three DQw2 cells associated with non-DR3 haplotypes and two DQwl +
cells, since d.2778 expressed DQwl, and both d.2778 and d.1417 the DQw2
antigens. Among the clones derived from d.1417 PBMC, four (clones 13, 16,
49, and 90) had maintained their reactivity to the autologous TT-pulsed cell.
Among the clones from d.2778, three (clones 5, 9, and 10) were still reactive,
and specific for TT; these clones were not stimulated by any of five other
antigens (diphtheria toxoid, candida antigen, proteus antigen, trichophyton
antigen, and tuberculin; see Material and Methods) tested using the autologous
APC. All these clones were CD3',CD4',CD8-. The results obtained with these
seven informative clones are shown in Table 1. None was restricted by DQwl-,
and DQw2-associated epitopes. Clone 10 proliferated only to one DR3 TT-APC.
This indicated restriction by a determinant distinct of DR3, or DQw, since none
of the other TT-DQw2+ DR3 or DR7 APC tested in this panel stimulated clone
10. More extended panel studies were therefore performed to define the restrict-
ing determinant of this clone.
The DR3-associated Restriction Polymorphism Defines Three Clusters within DRw52
TT-APC. The detailed specificities of these clones were explored against a panel
of unrelated irradiated APC that covered a large spectrum of HLA-DR specific-
ities. They were previously pulsed with TT or PBS. Clones 5, 9, 13, 90, and 49
reacted similarly and specifically to TT-DR3-APC. Representative results ob-
tained with clone 49 are shown on Table II. This contrasted with the results
obtained with clone 16 and clone 10 . Clone 16 reacted specifically only to some
TT-DR3-APC, and some TT-DRw6-APC. Interestingly, among four DR3 HTC
(AVL, HAR, CAA, QBL) tested, QBL failed to present TT to clone 16. Clone
10 proliferated specifically to approximately half of the TT-DR3-APC, all TT-
DR5-APC, and some TT-DRw6-APC. These TT-APC did not stimulate clone
16, except for three of the TT-DR5-APC that also expressed DR3, DRw52
encoded on the second haplotype (d.2757, d.521, d.891). Interestingly, clone 10TABLE I
ProliferativeResponsesofTetanus Toxoid (TT)-specificSelected Clones: Preliminary Screening
for DQtu2 Nonreactive Clones
IRLE ET AL.
￿
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* Results are expressed as means of triplicate cultures; standard deviation of the mean was always
<20%. Results in boldface indicate positive data.
$These were used forcloning, resultingin the cell lines shown in the table.
NT, not tested.
was stimulated by TT presented by the HTC QBL, and failed to react with the
other DR3 HTCs. Thus, the reactivity ofclones 10 and 16 reflects recognition
of mutually exclusive epitopes on TT-DRw52-APC.
The supratypic HLA-DRw52 specificity is almost perfectly associated with
HLA-DR3, -5, -w6, and -w8 by serology. Clone 16 was not stimulated at all and
clone 10 only very weakly by TT-DRw8 APC. This result indicates a significant
functional difference between HLA-DRw52 associated with HLA-DRw8 and
with HLA-DR3, -5, and -w6 haplotypes respectively. One TT-APC that ex-
pressed only one DRw52 allele (d.3135: HLA-DR2,w6;DRw52,-;DQwl,-) stim-
ulated both clones 10 and 16. This cell (a) failed to stimulate the alloreactive
LB-Ql-specific T cell line RT297, that otherwise overlapped completely with
the pattern of reactivity ofclone 10 (Table 11), and (b) differed from the other
DRw52 cells in the oligonucleotide typing experiments (see below and Fig. 4).
This result suggests the existence of a third restriction epitope of DRw52 in
some DRw6 haplotypes, in agreement with the identification ofa third allele of
DR (3111 (Gorski, J., et a1., manuscript in preparation).
Moderate alloreactivity ofclone 10 to 3 DR5 cells (among a total of 21 tested
DR5 APC) was noticed (Table 11). These three cells were DRw11. This alloreac-
Donor
number
Stimulator cells
HLAtyping
DR DQw
TT
+/-
['H]TdR incorporation*
Clones from donor 1417 Clones
13 16 49 90 5
from donor
9
2778
10
cpm x 10- cpm x 10-3
895 7,9 2,3 + 0.4 0.6 0.2 0.3 0.3 0.4 0.9
0.2 0.2 0.3 0.4 0.3 0.3 0.9
1213 6,7 1,2 + 0.2 0.3 0.1 0.4 0.1 0.2 1.3
0.4 0.1 0.2 0.3 0.1 0.2 1.3
2644 4,7 2,3 + 0.6 0.3 0.5 0.3 0.1 0.1 0.7
0.3 0.1 0.2 0.3 0.1 0.1 0.4
766 1,3 1,2 + 1.5 2.1 6.3 2.6 18.6 13.0 1.1
0.4 0.3 0.2 0.1 0.2 0.2 0.7
22 3,10 1,2 + 1.8 6.3 10.6 11 .8 35.3 18.2 0.7
0.3 0.2 1.0 0.2 0.6 0.3 0.4
1675 3,1 1,2 + 4.0 12.1 12.6 8.1 NT NT NT
0.4 0.4 0.6 0.1 NT NT NT
1417 3,- 2,- + 2.3 3.3 7.4 8.1 NT NT NT
0.4 0.4 0.4 0.2 NT NT NT
2190 3,4 2,3 + NT4 NT NT NT 46.2 84.5 2.5
NT NT NT NT 0.5 0.3 1.1
2778 3,6 1,2 + NT NT NT NT 17.0 8.1 21 .3
NT NT NT NT 0.1 0.1 0.7858 FUNCTIONAL POLYMORPHISM OF THE TWO DR R GENE PRODUCTS
TABLE 11
Distinct HLA-DRw-52 Epitopes Are Associated with the Restrictionfor TT-reactive
T Cell Clones
Stimulator cells ['H]TdR incorporation* (cpm X 10-g)
HLA typing TT Clone number tested Alloreac
tive line Donor
A B DR DQw +/- 49$ 16$ I0§ RT 27
AVL 1,1 8,8 3,3 2,2 + 15.3 1.9 0.7 -
0.1 0.1 0.7 0.2
HAR 1,1 8,8 3,3 2,2 + 15.6 2.0 1.2 -
0,1 0.1 1.2 NT'
CAA 1,1 8,8 3,3 2,2 + 33.5 3.1 0.7 -
0.1 0.2 0.7 NT
1417 1,- 8,21 3,- 2,- + 31.8 3.3 0.5 -
0.3 0.2 0.5 0.2
22 3,9 12,27 3,10 1,2 + 52.5 6.0 0.5 -
0.2 0.2 0.3 0.2
1678 19,- 12,21 3,7 2,- + 27.6 6.7 1.1 -
0.3 0.2 0.5 0.2
2037 1,2 15,35 3,- 2,- + 33.7 6.1 0.2 -
0.1 0.2 0.1 0.2
31591 1,- 8,- 3,7 2,- + 24.8 11 .3 0.6 -
0.1 0.1 0.6 NT
QBL 26,26 18,18 3,3 2,2 + 17.5 0.2 28.3
0.4 0.2 0.6 19.9
1874 1,2 17,18 3,7 2,- + 21.4 0.2 35.6
0.2 0.2 3.0 23.1
2778§ 2,3 5,12 3,6 1,2 + 20.9 0.3 45.4
0.2 0.2 0.4 43.2
2757 1,3 7,8 3,5 2,3 + 54.8 7.0 88.2
0.3 0.3 0.3 42.3
521 1,28 5,8 3,5 2,3 + 23.0 3.1 70.8
0.2 0.2 4.5 44.9
NM 1,24 8,57 3,5 2,3 + 28.0 3.2 40.4
0.1 0.2 0.4 11.7
891 2,9 15,22 3,5 2,3 + 65.2 1.5 90.6
0.4 0.3 0.5 29.9
497 11,- 14,35 5,1 1,3 + 0.2 0.2 5.2
0.3 0.3 0.5 33.8
673 1,19 12,17 5,2 1,3 + 0.3 0.3 60.0
0.3 0.2 17.5 48.3
1165 3,10 7,12 5,2 1,3 + 0.2 0.5 27.7
0.2 0.2 5.2 34.5
1104 9,24 7,12 5,2 1,3 + 0.5 0,3 37.8
0.2 0,3 1.0 36.3
KD 2,- 5,12 5,4 3,- + 0.2 0,2 10.7
0.1 0.2 0.3 NT
2657 9,19 12,21 5,7 2,3 + 0.1 0.2 26.1
0.2 0.1 0.2 19.8
JVM 2,2 18,18 5,5 3,3 + 0.2 0.1 30.7
0.1 0.1 0.1 1.3
ATH 25,25 18,18 5,5 3,3 + 0.3 0.1 39.6
0.2 0.1 0.2 16.0IRLE ET AL .
TABLE 1I-Continued
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Representative panel ofPBMC representing awide spectrum ofDR haplotypes, which were tested
as APC in the presence (+), or absence (-) of TT using clones 49, 16, and 10 as responders, as
describedin MaterialsandMethods . These clones were TT-specific when testedwith theautologous
APC and six different antigens including TT (see first section of Results and Materials and
Methods) . Boldface numbers represent cells 1417 and 2778 used for cloning, resulting in cell lines
tested,and represent positive results obtained in panel experiments .
* Data shown represent means of triplicate cultures; the standard deviation of the mean was always
<20% .
$ Clones 49 and 16 were obtained from donor 1417 .
4 Clone 10 was obtained from donor 2778 .
RT279 is specific for the LB-Q1 allodeterminant associated with DRw52 .
w NT,not tested.
tivity was most probably not due to DRw11, since among 16 DRw11 cells no
other one stimulated clone 10 in the absence ofTT . Furthermore, no alloreac-
tivity was observed with the DRwII HTC JVM, which seems to represent a
distinct DR5 (22), and which presented TT to clone 10 . Since no pattern of
association between alloproliferation and any HLA antigen was noticed, cross-
Stimulator cells ['H]TdR incorporation* (cpm x 10-s )
Donor
A
HLA
B
typing
DR DQw
TT
+/-
Clone
49$
number
16$
tested
10§
Alloreac-
tive line
RT 279 11
WAP 2,31 18,18 5,5 3,3 + 0.2 0.1 25.3 -
- 0.1 0.1 0.2 19.7
HHK 3,3 7,7 6,6 1,1 + 0.2 3.3 0.5 -
- 0.2 0.2 0.4 0.1
1213 11,19 12,44 6,7 1,2 + 0.2 2.1 0.5 -
- 0.2 0.1 0.4 0.2
2221 1,2 7,8 2,6 1,- + 0.2 0.2 33.4 -
- 0.2 0 .2 0.7 43.2
3135 3,32 7,8 2,6 1,- + 1 .0 10.7 13.9 -
- 0.2 0.2 0.4 0.3
2134 1,2 7,40 2,8 1,3 + 0.7 0 .2 3.0 -
- 0.1 0.1 0.2 0.3
2995 2,9 5,35 2,8 1,3 + 0.5 0.3 1 .4 -
- 0.1 0.2 0.2 0.2
1157 10,19 5,27 1,9 1,3 + 0.2 0.1 0.2 -
- 0.3 0.3 0.4 0.2
2913 3,31 15,37 1,10 1,- + 0.4 0.1 0 .3 -
- 0.3 0.3 0 .5 0.3
ES 3,10 12,35 1,10 1,- + 0.3 0.3 0 .2 -
- 0.2 0.2 0 .1 0.3
1484 2,- 12,18 2,4 1,3 + 0.2 0.2 0.3 -
- 0.3 0.2 0.5 0.1
658 2,3 7,21 2,7 1,2 + 0.3 0.3 0.5 -
- 0.2 0.5 0.4 0.2
863 2,- 13,15 4,7 2,3 + 0.3 0.7 0.3 -
- 0.2 1 .0 0.1 0.2
ET 1,2 8,40 4,7 2,3 + 0.1 0.2 0.3 -
- 0.1 0.2 0.2 0.1
895 1,2 13,27 7,9 2,3 + 0.2 0.3 0.7 -
- 0.2 0.2 0.5 0.2860 FUNCTIONAL POLYMORPHISM OF THE TWO DR 0 GENE PRODUCTS
TABLE III
Independent Segregation ofthe Restriction Determinants ofClone 16 and Clone 10 in
a Family Study
* ['H]TdR incorporation (cpm X 10-'); standard deviationof themean wasalways <20%. Results in
boldface indicate positive data.
reactivity between self + TT and an epitope that remains presently undefined
seems the most likely explanation ofthis observation.
Family Studies Demonstrate the Allelic Nature of the DRw52-related Restriction
Polymorphism. The panel studies showed distinct DR3, 5, and w6 haplotype-
associated restriction determinants included within the supratypic specificity
DRw52. Several DRw52 heterozygous APC stimulated both clones 10 and 16.
We therefore determined the segregation ofthe restriction with TT-APC from
families where DRw52 heterozygosity occurred as a consequence of parental
transmission of HLA-DR3-, -DR5-, and -DRw6-associated haplotypes. A typical
result ofsuch an experiment is shown on Table III. In this family (family R), as
well as in two others tested, DRw52 was transmitted on two distinct parental
haplotypesto thechildren. Clone 16 and clone 10 response patterns clearly allow
to segregate TT-APC with distinct DRw52-associated haplotypes in the family.
This demonstrates the functional significance of the allelic diversity within
DRw52.
The DRw52 Specificity ofthe T Cell Clones Is Not Affected by Variations in Antigen
Concentrations and HLA-DR Expression. Effective antigen presentation byAPCs
is thought to depend on the amount of antigen used during their incubation
before testing, and on the level of HLA-class 11 expression (23-25). These
factors were investigated using APCs that stimulated clone 16 or clone 10 in
previous experiments. First, we tested the response of the clones to APCs that
were incubated with TT dilutions ranging from 1:500 to 1:10,000. Increasing
antigen concentrations resulted in increased proliferation (Fig. 1). Secondly, the
influence of increased HLA-class II expression on the effectiveness of antigen
presentation was explored after overnight incubations of APCs with INF-y.
Increasing the level of DR expression augmented the magnitude ofthe specific
T cell clone response (Fig. 2). In these experiments the specific pattern of
reactivity ofclones 10 and 16 was not modified.
Inhibitor Effect of mAbs Specific for HLA-Class II Epitopes on Antigen-induced
Proliferation of Clones 49, 10, and 16. Blocking of restriction determinants by
mAbscan abrogate the response ofantigen-specific, restricted clones. To confirm
Donor
Stimulator cells
HLA haplotypes
TT-specific
Clone 16
proliferation*
Clone 10
Father: a: A10, B7, DR 1, -, DQw1 0.3 121.9
b: A28, B17, DR3, DRw52, DQw2
Mother: c: A9, B15, DR2, -, I
DQwl, - 4.9 0.2
d: A28, B27, DRw6, DRw52,
Sibling 1 b/d 2.1 12.1
Sibling 2 b/d 3.5 27.7
Sibling 3 a/d 1.9 0.3IRLE ET AL .
FIGURE 1 . Proliferation of
TT-specific T cell clones 49,
16, and 10 to TT-APC 1417
(autologousto clones 49 and
16, "- -0) and to TT-APC
2778 (autologous to clone 10,
0-0) . For APC-HLA typ-
ing see Table 11 . Clone 49
reacts to both TT-APC (both
DR3) . Clone 16 and 10 react
only to the autologous TT-
APC, which express diverse
DRw52 alleles . Antigen satu-
ration does notinduce reactiv-
ity of clone 10 and 16 to the
opposite DRw52 alleles .
FIGURE 2.
￿
Comparison between DR expression evaluated by fluorescence flow cytometry
analysis (FACS) and by antigen presentation after incubation of the APC in culture medium
without (A, darkFACS lines) or with INF-y (B, light FACS lines) . Experiments with TT-APC
from d.2778 (expressing the DRw52b allele), respectively d.31591 (expressing the DRw52a
allele, oligonucleotide typing result notshown elsewhere) areshown . TT presentation is tested
with clone 10, and clone 49, INF-y increasedDR expression by bothAPC (by --0.5 log) . The
response of clone 10 to TT-APC 2778 increased significantly, and no response to TT-APC
31591 was seen, even afterINF-y . After this treatment, the response of clone49 to both TT-
APCs increased significantly .
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FIGURE 3 .
￿
Blocking of TT-specific responsesofclone49 (/)and ofclone 10 (E3) toTT-APC
(B-LCL DUCAF, HLA-DR3,3;DRw52,w52) by mAbs antibodies tested in increasing dilutions
is shown . Results are shown in percent relative responses to TT-APC without mAb, and
determinedas indicated in MaterialsandMethods. Error bars represent the standard deviations
of the triplicates . mAb GSP41 and D1/12 (DR framework) differentially block antigen
presentation to both clones, in contrast tomAb Tu 35, which completely inhibits both clones
at all concentrations tested. ThemAb 16.23 (DR3 + some DRw6) inhibits clone 49 only, in
contrast to the mAb NDS10 (DRw52-like) that inhibits only clone 10 . mAb Tu 22 (DQ
framework) dose not inhibit significantly at dilutions 1 :200 and greater, and mAbB7/21 never
blocked .
that the restriction determinants of clones 49, 10, and 16 relate to molecules of
the DR family, and not to DQ or DP,T cell clones 49, 10, and 16 were tested
for their specific proliferation to TT-APC incubated with mAbs specific for
monomorphic determinants of the DR, DQ, and DP molecules . Some results of
blocking experiments illustrating this point are shown in Fig. 3 . All three clones
were significantly blocked by anti-DR mAb GSP 4.1, D1/12, and Tu35 . Differ-
ential blocking was observed between clone 49 and clones 10 and 16 (Fig . 3
shows clones 49 and 10 only, since inhibition of clones 10 and 16 were similar) .
Since DR3 and DRw52 epitopes are located on distinct DR molecules (7), the
differential blocking is probably due to different framework antibody binding
sites of these two molecules. Differential blocking by distinct mAbs of antigen-
specific DR-restricted T cell clones was related by others (26) to recognition of
functional epitopes on the DR molecules by some mAb only . The anti-DQ mAb
Tu 22 inhibited the DR3- and the DRw52-restricted clones at very high concen-
trations (1 :40) . This inhibition was no longer seen when the antibody was diluted
further . Since the anti-DP mAb B7/21 did not block these clones at similar
concentrations, nonspecific inhibition seems unlikely . The best interpretation ofIRLE ET AL.
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these findings is that weak binding of Tu 22 to a DR-associated epitope occurs
at high antibody concentrations.
Additional evidence that the restriction determinants ofthe clones mapped to
DR3, respectively to DRw52 alleles, was obtained in blocking experiments with
mAb 16.23 (specific for DR3 and some DRw6), NDS10 (specific for some
DRw52), and 7.3.19.1 (specific for a DRw52-like epitope) . The mAb 16.23
blocked the DR3-restricted clone 49 but not the DRw52-restricted clone 10. In
contrast, mAb NDS10 blocked clone 10, but not clone 49. The mAb 7.3.19.1
blocked all the clones (data not shown), suggesting binding to an epitope shared
by both DR molecules. These results provide additional evidence for distinct
functional epitopes of DR molecules containing the DR3 and the DRw52 speci-
ficities.
Correlation between the Reactivities of Clones 10 and 16 and the Allelic Series
Defined at Locus DR ,BH1 by Oligonucleotide Hybridization. The experiments
described above provide evidence for functional epitopes that map to distinct
alleles of DRw52. These are associated with the haplotypes of the HTCs AVL,
QBL, and d.3135, respectively. DNA sequencing studies have shown that the
DR3 HTC AVL and QBL are respectively 52a and 52b at their DR #III locus,
and have identified a third allele named 52c in some DRw6 haplotypes (Gorski,
J., et al., manuscript in preparation).
Since the Tcell clones described here also distinguish AVL and QBL, we have
determined the segregation of 52a and b alleles as well as of the 52c allele by
oligonucleotide typing in panel cells and families that had been studied with
clones 49, 10, and 16. A selection of results obtained using the cells listed in the
panel studies (represented in Table II) are shown on Fig. 4. These studies
demonstrate a complete correlation between the DRw52a oligonucleotide hy-
bridization pattern and the reactivity ofclone 16. Similarly, there was a complete
overlap in the hybridization of the oligonucleotide specific for 52b and the
reactivity ofclone 10. The d.3135 TT-APC that had stimulated both clones but
not the alloreactive LB-Q1-specific T cell line RT279, was typed DRw52c using
the DRw52c oligonucleotide probe. The epitope recognized by the LB-Q1-
specific T cell line RT279 is absent from this allele.
The correlation between the functionally defined determinants restricting the
TT-specific reactivity of clone 16 and of clone 10 with the 52a and the 52b
alleles defined by oligonucleotide typing in the panel experiments was confirmed
in family studies. The results obtained with one informative family (family R)
are shown (Fig. 5). These results demonstrate the functional and structural
correlation between the alleles of locus DR ,8111.
Discussion
Within the class II region ofhuman HLA haplotypes, the HLA-DR subregion
contains a variable number of,Q chain genes differing in their polymorphism (3,
4, 8). The DR restriction of antigen-specific T cell responses is believed to be
associated with the highly polymorphic ,B gene chain, that most likely contains
the epitope(s) recognized by the alloantigen-specific DR sera. This poses the
question of the functional role of the less polymorphic 0111 locus expressed in
most haplotypes. We have shown recently with the use oftransfected L cells that86)4 FUNCTIONAL POLYMORPHISM OF THE TWO DR R GENE PRODUCTS
FIGURE 4 . Panel cells used to characterize clones 49, 10, and 16 were analyzed using
oligonucleotideDNAtyping for DRw52a, 52b, and52c alleles . The oligonucleotide sequences
and their uses are described in Materials and Methods. Serological DR typing and cell
identification numbers are indicated above each lane . Arrows point to the Eco RI 3.3-kb
fragment corresponding to the first domain exon . The oligonucleotide typing results (52a, b,
or c) are indicated under each lane, together with the reactivity (+/-) ofeach ofthe cells with
clones 10 and 16, as described in Table II . Expression of the LB-QI determinant, recognized
by theT cell line RT279, is also indicated .IRLE ET AL .
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FIGURE 5. Oligonucleotide DNA typing
analysis of the family R for DRw52a, b, and
c alleles performedas described in Materials
and Methods . Each lane contains Eco RI-
digested genomic DNA from family mem-
bers whose DR typing is shown . (F, father ;
M, mother ; SI-S3, siblings) . The typing
results are indicated under each lane, and
compared with the results obtained with
clones 10 and 16 . Expression of the LB-Q1
determinant, recognized by theT cell line
RT279, is also indicated.
this DR #III locusencodesthe serologically defined supratypic DRw52 specificity
(7) and that three alleles of #III can be recognized by DNA sequencing (4, and
Gorski, J., et al ., manuscript in preparation) . These three alleles can now be
identified by oligonucleotide typing (5, 8, 9) . Studies with alloreactive and
antigen-specific T cell lines have also indicated the existence of polymorphism
within DRw52 haplotypes (12, 27, 28, and Sheehy, M . J ., personal communica-
tion) . The relation between functional MHC restriction polymorphism, MHC
polymorphism recognized by alloreactiveT cells, and structural MHC polymor-
phism is presently unclear . We have therefore explored the functional relevance
of each of the DR # chain loci with antigen-restricted T cell clones .
The correlation between these functional studies and oligonucleotide typing
of the panel and family cells indicated that the restriction determinants for TT
could be mapped to the polymorphic domains of the DR 01 as well as the DR
0111 gene products . This was shown by the direct correlation between the
response pattern of clone 49 and DR3, between clone 16 and the 52a-specific
oligonucleotide, between the response pattern of clone 10 and the 52b specific866 FUNCTIONAL POLYMORPHISM OF THE TWO DR ,B GENE PRODUCTS
probe, and between the response by both clones to d.3135 that typed 52c with
the specific oligonucleotide. Since these clones are restricted by epitopes mapping
to each of the DR ,Q loci, the DR #II1 gene product is therefore functional and
contributes to antigen-specific T cell responses.
Previous indications of heterogeneity within DRw52 were obtained with allo-
reactive T cell clones (12, 27, 28, and Sheehy, M. J., personal communication),
and with mAbs (11). However, most determinants that can be recognized by
such reagents are not relevant for antigen presentation, which seems to be the
primary function of MHC molecules. Indeed, restriction by class II molecules
may only involve a single antigen binding site (1, 29). In this respect, the present
studies differ fundamentally from these previous reports of DRw52-associated
diversity, since they are based on antigen presentation, and therefore describe a
functionally relevant polymorphism within DRw52. Our results also indicate a
direct correlation between these newly recognized functional epitopes and the
structural polymorphism of the DR ,8111 genes identified by DNA sequencing
and by locus- and allele-specific oligonucleotide probes.
The supertypic DRw52 specificity comprises not only DR3, 5, and w6 but also
DRw8. The lack ofsignificant reactivity of our DRw52-restricted allele-specific
clones to all TT-DRw8-APC tested, together with the lack of stimulation of the
alloreactive LB-Q1-specific T cell line RT279 by DRw8 cells (12, and results
shown in Table II), and the failure ofseveral mAbsspecificfor DRw52-associated
epitopes to recognize DRw8 cells (18, Fuggle, S. V., manuscript submitted for
publication) suggest a structural particularity of DRw8. The failure of DRw52
locus-specific oligonucleotide probes to hybridize with DNA from two of these
DRw8 cells analyzed suggests that the serologically defined DRw8-associated
DRw52 specificity in not due to any one of the three alleles identified at locus
DR #111 by these reagents. Since RFLP studies ofDRw8cellssuggest the presence
of only a single DR ,3 chain gene (30), the best interpretation is that DRw8
individuals have only one DR flI locus whose product is recognized by DRw52
antisera through a DRw52 framework epitope.
The main restriction determinants for antigen presentation appear to relate
to HLA-DR, rather than to HLA-DQw, or -DP gene products, although these
latter can function as restriction determinants (31-33). Despite the considerable
heterogeneity among the polypeptides in TT preparations, allowing for multiple
antigen-class II associations, the functional DR specificities seem to occur pri-
marily with the product of the DR #I gene. This is suggested by the more
frequent finding of DR3-restricted T cell clones compared with DRw52-re-
stricted T cell clones in several cloning experiments with cells from different
donors. The possibility of immunodominance of DR )31-controlled restriction
could reflect differences in the level of expression of the DR antigens rather
than intrinsic functional differences, ora bias in the T cell repertoire, or receptor
affinity. This view is supported by recent findings showing that the DR 01 locus
is expressed about three- to fivefold more than locus DR #111 at the mRNA level
in peripheral blood lymphocytes and monocytes (34). Sequential immunoprecip-
itation studies have also suggested an excess of DR 01 gene product (25). Finally,
we show that INF-y-treated APC that express more DR molecules have an
increased efficacy in TT presentation to T cell clones, and this for both DR /3IRLL ET AL.
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gene products. The influence of the level of MHC expression, including its
abberant expression on T cell responsiveness was already illustrated by several
experiments in animal and human systems (23, 24, 35). These observations point
out that modifications in the regulation of HLA-class II gene expression might
influence the pattern of T cell reactivity through an increased availability of
functional class II epitopes. This could play a crucial role in the pathogenesis of
autoimmunity (3).
The function of the DR ,8111 locus product in antigen presentation and in
allelic restriction is of particular interest in view of the drastically different
patterns of amino acid sequence diversity between the DR ,81 and the DR ,8111
gene products. This is illustrated in Fig. 6 with two examples. In the DR3, -5,
and -w6 haplotypes, DR #1 alleles differ almost exclusively at a small hypervari-
able segment around amino acids 67 and 74, while the alleles of locus DR #III
vary by dissimilarities that are scattered throughout the first domain (3, 4).
Therefore, the finding of antigen-specific T cell clones restricted by either locus
DR (31 or DR 0111, and discriminating between the newly recognized DRw52
alleles at locus DR flIII, can help us to understand the structural nature of the
DR determinants responsible for antigen presentation to T cells.
The basis for this isotypic and allelic distinction by antigen-specific T cells is
the amino acid sequence of each of the relevant DR 0chains (DR3 ,#I, DRw6 (#1,
DRw52 ,8111 a, b, and c). These are analyzed in Fig. 6. Despite the considerable
sequence homology between the DR ,BI chain of DR3 and DRw6, no functional
crossreactivityoccurred between therestriction sites encoded by thesetwo alleles.
As discussed elsewhere (4), a gene conversion event has resulted in the introduc-
tion of two novel amino acids from a DR #III 52a sequence into a DR 01 DRw6
sequence, and this new DR 0 chain sequence determines the DR3 01 specificity.
DR3-restricted T cell clones recognize only the product of the converted gene
(DR3 01), and not the DRw6 ,#I or 0111 products. Furthermore, the DRw52a-
restricted clone 16 does not react with the DR3 #1 product (expressed on
DR3/DRw52b cells), despite the presence within the DR3 X31 polypeptide of
elements of the 52a sequence (Fig. 6). Thebasisfor T cell discrimination between
DR3 and DRw6 is therefore not the individual amino acid sequence but rather
the conformational change in the DR 01 chain modified by conversion (4). This
interpretation is also in agreement with studiescorrelatingstructureand function
by site-directed mutagenesis. These experiments showed that conformational
changes that modify H-2 specificities can arise at a site that is distant from the
mutagenized region (36-38).
The structural basis for the functional discrimination between the newly
recognized DRw52 alleles at locus DR ,8111 can also be deduced from the amino
acid sequence comparisons. In contrast to the clustering of sequence differences
between 01 locus products in the hypervariable region defined between a.a. in
position 67-74, differences between 0111 alleles are scattered throughout the
first domain and only one amino acid difference (R/Q) is located within the
segment corresponding to the hypervariable region of #I (Fig. 6).
The structural basis for functional allelic determinants might thus be different
for DR flI and DR 0111 gene products. Recent experiments have suggested that
the physical basis for restriction might result from qualitative differences in the868 FUNCTIONAL POLYMORPHISM OF THE TWO DR )3 GENE PRODUCTS
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interaction between antigen and an antigen binding site on class II molecules (1,
29, 39, 40), each class II molecule presenting a limited number of antigenic
peptides selectively (40). The basis for restriction seems therefore to be a
consequence of complementarity between a segment of the class II molecule
itself and the antigen, rather than direct class II recognition by the TCR (1, 41) .
Since restriction is linked to DR polymorphism, the antigen binding site of class
II molecules is probably encoded by the polymorphic region. In this respect, it
is of interest to observe that DR ,8111-encoded class II molecules are functional,
although they have a very distinct pattern of allelic structural diversity (sequence
differences are scattered) when compared with sequence differences between
DR #1 products that are limited to a short hypervariable segment. This distinction
in the structural basis of polymorphism between DR ,BI and DR #III could result
in a difference of their number of antigen binding sites, thereby increasing the
chances of effective antigen-class II interaction.
Summary
HLA-DR3- and HLA-DRw52-associated functional polymorphism was inves-
tigated with selected tetanus toxoid (TT)-specific T cell clones. We have shown
earlier that HLA-DR antigens are encoded by two distinct loci, DR 01 and DR
,8111. The alloantigenic determinant(s) defined by the serological HLA-DR3
specificity map to the former, while the supratypic HLA-DRw52 determinants
map to DR #III. Furthermore, we have recently recognized by DNA sequencing
three alleles of HLA-DRw52 at locus DR #III, referred to as 52 a, b, and c.
Our objective was to correlate the pattern of T cell restriction with the gene
products of individual DR ,l chain loci and with the three newly described alleles
of locus DR #II1. Among the selected T cell clones, 5 reacted exclusively when
TT was presented by HLA-DR3+ APCs (TT-DR3-APC). In contrast, two T cell
clones were stimulated by TT-DRw52-APC. More specifically, these two T cell
clones (Clones 10 and 16) were stimulated by different subsets of TT-DRw52-
APC. Clone 16 responded to some DR3 and TT-DRw6-APC, while clone 10
was stimulated by other TT-DR3 and TT-DRw6, and all TT-DR5-APC. This
same pattern of DRw52 restriction was found in panel, as well as in family
studies. Because this suggested a correlation with the pattern of DRw52 poly-
morphism observed earlier by DNA sequencing and oligonucleotide hybridiza-
tion, the APC used in these experiments were typed for the 52 a, b, and c alleles
of locus DR X3111 by allele-specific oligonucleotide probes. This distribution
overlapped exactly with the stimulation pattern defined by the T cell clones.
Clone 16 responded to TT-52a-APC, clone 10 to TT-52b-APC, and both clones
to a TT-52c-APC. The response of the T cell clones was inhibited differentially
by mAbs to DR. Raising TT concentration, or increasing HLA-class II expression
with INF-y both affected the magnitude of response of the TT-specific clones
but did not modify their specificities.
These results demonstrate that a restriction specificity can be attributed to the
DR ,8111 locus and illustrate the functional relevance of the polymorphism
observed at this locus. This is of special interest in view of the striking difference
in the pattern of structural diversity among alleles of DR ,BI and DR ,8111.870 FUNCTIONAL POLYMORPHISM OF THE TWO DR 9 GENE PRODUCTS
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